RLAY
Relay Therapeutics, Inc.NASDAQHealthcare$12.54+16.43%ClosedMarket Cap: $2.24B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.77
P/S
144.90
EV/EBITDA
-7.48
DCF Value
$-0.88
FCF Yield
-10.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-1971.5%
Net Margin
-1800.5%
ROE
-43.2%
ROA
-44.5%
ROIC
-50.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $7.0M | 91.4% | $-60.6M | $-54.9M | $-0.32 | — |
| FY 2025 | $15.4M | 76.8% | $-302.7M | $-276.5M | $-1.61 | — |
| Q3 2025 | $0.00 | -Infinity% | $-80.4M | $-74.1M | $-0.43 | — |
| Q2 2025 | $677.0K | 100.0% | $-76.8M | $-70.4M | $-0.41 | — |
| Q1 2025 | $7.7M | 100.0% | $-84.9M | $-77.1M | $-0.46 | — |
| Q4 2024 | $0.00 | NaN% | $-85.0M | $-76.0M | $-0.45 | — |
| FY 2024 | $10.0M | 100.0% | $-372.5M | $-337.7M | $-2.36 | — |
| Q3 2024 | $0.00 | NaN% | $-96.4M | $-88.1M | $-0.63 | — |
| Q2 2024 | $0.00 | NaN% | $-100.8M | $-92.2M | $-0.69 | — |
| Q1 2024 | $10.0M | 100.0% | $-90.4M | $-81.4M | $-0.62 | — |
| Q4 2023 | $-1.0K | 100.0% | $-92.2M | $-83.5M | $-0.68 | — |
| FY 2023 | $25.5M | 100.0% | $-373.0M | $-342.0M | $-2.79 | — |